News

Kampmann IND UCSF CRISPR

CRISPR-based genetic screens are a powerful technology to elucidate disease mechanisms and identify potential therapeutic strategies. However, the experimental design of a successful screen remains a challenge. Graduate student Tamas Nagy and IND faculty Dr. Martin Kampmann developed a simulation tool for these screens, termed CRISPulator, which helps researches to optimize the experimental parameters of different types of CRISPR-based screens. CRISPulator helped to uncover new rules for optimal screen design. The research was published in an article in BMC Bioinformatics:... Read more ...

Kampmann CRISPR UCSFIND faculty Martin Kampmann was featured as an Emerging Investigator in an annual Special Issue of Chemical Communications, the journal by the Royal Society of Chemistry.

He was recognized for his contributions to the development of innovative genetic screening technologies in mammalian cells and their application to identify the target of new drugs. Dr. Kampmann describes this research in a feature article in the same issue (Kampmann, M. [2017] Elucidating drug targets and mechanisms of action by genetic screens in mammalian cells. Chemical Communications 53: 7162–7167... Read more ...

Along with collaborators Mark von Zastrow and Brian Shoichet, IND faculty member Jeremy Willsey was awarded a Bold & Basic grant from the UCSF Quantitative Biosciences Institute to investigate new therapeutic targets for autism spectrum disorder by examining the underlying genetics, networks, and molecular pathways involved in these conditions. Watch a short video about their winning project below. Congrats to the research team!



Results Point to ‘Bright Future’ for Understanding Disorder

By Nicholas Weiler on May 3, 2017

Tourette disorder (also known as Tourette syndrome) afflicts as many as one person in a hundred worldwide with potentially disabling symptoms including involuntary motor and vocal tics. However, researchers have so far failed to determine the cause of the disorder, and treatments have only limited effectiveness, in part because the genetics underlying the disorder have remained largely a mystery.

Now, as reported online May 3, 2017, in Neuron, a consortium of top researchers – led by scientists at UC San Francisco, Rutgers University, Massachusetts General Hospital, the University of Florida and Yale School of Medicine – has made a significant advance, identifying the first “high-confidence” risk gene for Tourette disorder as well as three other probable risk... Read more ...

Pages